E-Therapeutics PLC
LSE:ETX
E-Therapeutics PLC
LSE:ETX
Price:
9 GBX
-6.74%
Market Closed
Updated:
May 24, 2024
E-Therapeutics PLC
Operating Expenses
|
E-Therapeutics PLC
Operating Expenses Peer Comparison
Comparables:
CNTA
AUTL
BCYC
IMCR
GNS
Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
E-Therapeutics PLC
LSE:ETX
|
Operating Expenses
-£10.7m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-7%
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Operating Expenses
-$178.1m
|
CAGR 3-Years
-157%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Operating Expenses
-$177.2m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Operating Expenses
-$221.4m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Operating Expenses
-£308m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Operating Expenses
-£620.1m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-7%
|
See Also
What is E-Therapeutics PLC's Operating Expenses?
Operating Expenses
-10.7m
GBP
-10.7m
GBP
Based on the financial report for Jan 31, 2023, E-Therapeutics PLC's Operating Expenses amounts to -10.7m GBP.
What is E-Therapeutics PLC's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-7%
-7%
Over the last year, the Operating Expenses growth was -7%. The average annual Operating Expenses growth rates for E-Therapeutics PLC have been -47% over the past three years , -10% over the past five years , and -7% over the past ten years .
You don't have any saved screeners yet
